Table 2.
Estimated Relative Treatment Effects As Odds Ratios (ORs) And Its Corresponding 95% Credibility Intervals (CrIs)
| Treatment | Apixaban | Edoxaban | Rivaroxaban | Dabigatran Etexilate | Conventional Therapy |
|---|---|---|---|---|---|
| Apixaban | – | 1.09 (0.63–1.79) | 1.79 (1.14–2.86) | 1.56 (0.96–2.56) | 1.30 (0.93–1.89) |
| Edoxaban | 0.91 (0.56–1.58) | – | 1.61 (1.04–2.86) | 1.43 (0.88–2.56) | 1.16 (0.85–1.92) |
| Rivaroxaban | 0.56 (0.35–0.88) | 0.62 (0.35–0.96) | – | 0.88 (0.54–1.40) | 0.73 (0.54–1.00) |
| Dabigatran Etexilate | 0.64 (0.39–1.04) | 0.70 (0.39–1.14) | 1.34 (0.71–1.85) | – | 0.82 (0.59–1.22) |
| Conventional Therapy | 0.77 (0.53–1.07) | 0.86 (0.52–1.18) | 1.37 (1.00–1.85) | 1.22 (0.82–1.69) | – |
Notes: Comparisons should be read from left to right. The estimate is located at the intersection of the column-defining treatment and the row-defining treatment. An OR value higher than 1 favors the column-defining treatment. An OR value lower than 1 favors the row-defining treatment.